Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALNA

Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Allena Pharmaceuticals logo

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Key Stats

Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
96,558 shs
Average Volume
15.69 million shs
Market Capitalization
$37,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

Allena Pharmaceuticals Inc ALNAQ Stock Quote
Allena Pharmaceuticals Inc (ALNAQ)
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
San Francisco Pharmaceuticals News
ALNA.O
See More Headlines

ALNA Stock Analysis - Frequently Asked Questions

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) released its quarterly earnings results on Thursday, March, 31st. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.06.

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB) and Zomedica (ZOM).

Company Calendar

Last Earnings
3/31/2022
Today
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$37,000.00
Optionable
Not Optionable
Beta
1.13
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:ALNA) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners